Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)

Significant advances in molecular nuclear medicine imaging in prostate cancer have been achieved in recent years. In particular, the introduction of prostate-specific membrane antigen (PSMA) -based tracers has significantly influenced diagnostic imaging of prostate. If cancer recurs after surgical removal of the prostate, targeted PSMA PET (positron emission tomography) can detect metastases even at very low PSA (prostate-specific Antigen) values. This increasingly allows individualized specific therapy of patients with prostate cancer recurrence. PSMA PET has now been included in national and

Trial Details

NCT ID
NCT04271579
Phase
NA
Sponsor
Martini-Klinik am UKE GmbH
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Salvage Lymphnode dissection
Locations (sample)
  • Hamburg, Germany|53.55073,9.99302

Key Eligibility Criteria

  • Patients in good general condition with life expectancy\> 10 years
  • Hormone-sensitive prostate cancer recurrence after radical prostatectomy (patients with status post salvage prostatectomy may be included; salvage …
  • Unilateral detection of ≤ 3 PSMA PET positive lymph node metastases in the pelvis (up ot origin of the inferior mesenteric artery)
  • PSA at the time of PSMA PET imaging \<4 ng / ml

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →